drugset / Trial / NCT00605085

Safety and Tolerability of the Japanese Encephalitis Vaccine IC51

NCT00605085

Phase 3 Completed 2675 enrolled Valneva Austria GmbH
RandomizedParallel-groupDouble-blindPrevention

Summary

The objective is to investigate the safety and tolerability of Japanese Encephalitis vaccine IC51 with an inactive control in healthy subjects aged \> or = 18 years

Timeline

Start
2005-10
Primary completion
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject IC51 Vaccine 6 ug Intramuscular

Indications